Cytokine-mediated CAR T therapy resistance in AML

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the efficacy seen in B cell malignancies. Here we report a pilot study of autologous anti-CD123 CAR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2024-12, Vol.30 (12), p.3697-3708
Hauptverfasser:	Bhagwat, Anand S., Torres, Leonel, Shestova, Olga, Shestov, Maksim, Mellors, Patrick W., Fisher, Han R., Farooki, Saamia N., Frost, Benjamin F., Loken, Michael R., Gaymon, Avery L., Frazee, Diane, Rogal, Walter, Frey, Noelle, Hexner, Elizabeth O., Luger, Selina M., Loren, Alison W., Martin, Mary Ellen, McCurdy, Shannon R., Perl, Alexander E., Stadtmauer, Edward A., Brogdon, Jennifer L., Fraietta, Joseph A., Hwang, Wei-Ting, Siegel, Don L., Plesa, Gabriela, Aplenc, Richard, Porter, David L., June, Carl H., Gill, Saar I.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/2325 631/67/1990/283/1897 Acute myeloid leukemia Adult Aged Antigens Biomedical and Life Sciences Biomedicine Cancer Research CD123 antigen Cell survival Cell therapy Chimeric antigen receptors Cytokine Release Syndrome - immunology Cytokine storm Cytokines Cytokines - immunology Cytokines - metabolism Disease resistance Drug Resistance, Neoplasm - immunology Effectiveness Female Humans Immunotherapy Immunotherapy, Adoptive - methods Infectious Diseases Kinases Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - therapy Lymphocytes Lymphocytes T Male Malignancy Metabolic Diseases Middle Aged Molecular Medicine Neurosciences Pilot Projects Receptors Receptors, Chimeric Antigen - immunology T-Lymphocytes - immunology Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!